6276 related articles for article (PubMed ID: 24245755)
1. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
4. [Prospects for the development of new antituberculous drugs putting our hopes on new drug targets].
Tomioka H
Kekkaku; 2010 Nov; 85(11):815-22. PubMed ID: 21174739
[TBL] [Abstract][Full Text] [Related]
5. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
6. [Prospects for the development of new antituberculous drugs based on the drug targets related to virulence factors interfering with host cytokine networks].
Tomioka H
Kansenshogaku Zasshi; 2012 Nov; 86(6):715-22. PubMed ID: 23367846
[TBL] [Abstract][Full Text] [Related]
7. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
Tomioka H
Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
[TBL] [Abstract][Full Text] [Related]
8. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
9. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
10. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.
Tomioka H
Curr Pharm Des; 2006; 12(31):4047-70. PubMed ID: 17100611
[TBL] [Abstract][Full Text] [Related]
11. Targeting type VII/ESX secretion systems for development of novel antimycobacterial drugs.
Bottai D; Serafini A; Cascioferro A; Brosch R; Manganelli R
Curr Pharm Des; 2014; 20(27):4346-56. PubMed ID: 24245757
[TBL] [Abstract][Full Text] [Related]
12. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
13. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
Tomioka H; Tatano Y; Sano C; Shimizu T
J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
[TBL] [Abstract][Full Text] [Related]
14. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
[TBL] [Abstract][Full Text] [Related]
15. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
Martins F; Ventura C; Santos S; Viveiros M
Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
[TBL] [Abstract][Full Text] [Related]
16. Design of novel quinoline-aminopiperidine derivatives as
Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
[TBL] [Abstract][Full Text] [Related]
17. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
18. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
Saxena AK; Singh A
Curr Top Med Chem; 2019; 19(5):337-355. PubMed ID: 30806318
[TBL] [Abstract][Full Text] [Related]
19. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
20. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]